Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples